PERSONAL INFORMATION
Birthdate: 03-09-1975
Birthplace: Bologna
Nationality: Italian
EDUCATION
Liceo Scientifico Statale “A.B. Sabin”, Bologna
Maturità Scientifica, 60/60.
University of Bologna
Master of Science in
Biology, 110/110 cum laude (15/07/1999)
Thesis title: “Cyclin A expression in primary infiltrating
breast carcinoma: a novel reliable indicator of the growth
fraction”.
University of Bologna
Specialization in Food Chemistry and
Technologies, 70/70 cum laude (08/03/2002)
Thesis title: “Functional foods: chemical and nutritional
aspects”.
University of Bologna
PhD in Clinical and Experimental
Hematology (05/06/2007)
Tesis title: "Abl kinase domain mutations as a mechanism of
resistance to tyrosine kinase inhibitors in Philadelphia-positive
leukemias: biological, clinical and prognostic relevance".
PROFESSIONAL EXPERIENCE
•
01/03/1998 -14/07/1999
Department of Radiological and Histopathological Sciences,
Section of Pathologic Anatomy, S.Orsola-Malpighi Hospital,
Bologna
Graduate Student internship
•
15/09/1999 – 01/04/2012
Institute of Hematology and Medical Oncology “L. e A.
Seràgnoli”, University of Bologna
Pre- and post-doctoral research fellowship at the
Molecular Biology Unit
• since
02/04/2012
Department of Hematology/Oncology “L. e A.
Seràgnoli”, now Department of
Experimental, Diagnostic and Specialty Medicine,
University of Bologna
Assistant Professor, SSD MED/15
• since 11/04/2022
Department of Hematology/Oncology “L. e A. Seràgnoli”, now Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna
Associate Professor, SSD MED/15
SCIENTIFIC ACTIVITY
-
Reviewer for the following international cancer journals: Blood;
Leukemia; Haematologica/The Hematology Journal; Clinical Cancer
Research; Cancer; Acta Haematologica; Leukemia Research; Cancer
Letters; Annals of Hematology; Clinical and Experimental Medicine;
Drug Discovery Today; Cancer Treatment Reviews; Leukemia Treatment
and Research; Anti-Cancer Drugs.
- Abstract
reviewer for the Meetings of the European Hematology
Association (EHA; 2008, 2009, 2013, 2015), of the American Society
of Hematology (ASH; 2009, 2015), of the Italian Society of
Experimental Hematology (SIES; 2010, 2012, 2014) and for the
European School of Hematology (ESH) International Conference on CML
(2011, 2012).
- Reviewer
of a grant application for the Kay Kendall Leukemia
Foundation (2009).
- Reviewer of a grant
application for the German-Israeli Foundation for Scientific
Research and Development (GIF) (2013).
- Reviewer
of a grant application for the National Science Center (Narodowe
Centrum Nauki – NCN), Poland.
- Reviewer
of applications for post-doctoral positions at the Universities
of Padua and Insubria (2012, 2013).
- Member
of the Editorial Board of “TheScientificWorld Journal”
(I.F. 1.524).
- Member
of the Italian Society of Hematology (SIE), the Italian
Society of Experimental Hematology (SIES),
the American Association for Cancer Research (AACR), the
American Society of Hematology (ASH) and the Society of
Hematological Oncology (SOHO).
- Member
of the Molecular Biology Committee of the GIMEMA CML
Working Party.
- Member of the Educational
Committee of the Society of Hematological Oncology (SOHO).
- Member of the Scientific
Program Committee Advisory Board of the 2015 Annual Meeting of
the European Hematology Association (EHA).
- Member
of the Scientific Program Committee of the Annual Meetings of the
European Hematology Association (EHA) for the years 2016 and
2017.
- Leader
of the "CML" workpackage within the IRON (Interlaboratory
RObustness of Next-generation sequencing) study II.
- Invited
speaker at 142 national and international meetings; attendee at 72
national and internation meetings; scientific committee member at 2
national meetings.
PARTICIPATION IN RESEARCH PROGRAMMES
“Tyrosine kinases as molecular targets for the therapy of
acute and chronic leukemias”; Scientific Coordinator of the
project, Prof. Michele Baccarani; duration, 24 months.
- EUROPEAN LEUKEMIANET (ELN)
funded by EU, Sixth Framework Programme; duration, 60
months.
“ Characterization of the molecular mechanisms responsible for
sensitivity and resistance of philadelphia-positive cells to
tyrosine kinase inhibitors”; Scientific Coordinator of the project,
Prof. Giuseppe Saglio; Scientific Coordinator of the Research Unit,
Prof. Michele Baccarani; duration, 24 months.
- FIRB 2006 – IDEE PROGETTUALI
“Studio e trattamento dei tumori e delle malattie degenerative:
sviluppo e produzione di una nuova piattaforma analitica in DHPLC
(Denaturing High Pressure Liquid Chromatography) completa di test
diagnostici dedicati ai differenti settori applicativi in oncologia
e nelle malattie degenerative”; Scientific Coordinator of the
project, Prof. Giovanni Martinelli; duratiom, 36 months.
“Hematopoietic stem cells in chronic myeloid
leukemia: biological and clinical effects of tyrosine
kinase inhibitor treatment”, prot 2007F7AE7B_002; Scientific
Coordinator of the project, Prof. Fabrizio Pane; Scientific
Coordinator of the Research Unit, Prof. Michele Baccarani;
duration, 24 months.
“Mechanisms responsible for sensitivity and resistance of
Ph-positive cells to tyrosine kinase inhibitors”, Scientific
Coordinator of the project, Prof. Giovanni Martinelli; duration, 36
months.
“Control mechanisms of Ph1+ stem cells: prognostic
implications and therapeutic applications ” prot
2009JSMKYE; Scientific Coordinator of the project, Prof. Michele
Baccarani; durata, 24 mesi. Scientific Coordinator of a
Research Unit from 12/12/2012.
- FP7-HEALTH-2012-INNOVATION-1 - Seventh Framework
Programme 2011
"Next Generation Sequencing platform for targeted Personalized
Therapy of Leukemia" – (Acronym: NGS-PTL) Scientific Coordinator of
the project, Prof. Giovanni Martinelli; duration, 36 months.
AWARDS AND HONORS
- 2007 AACR-GlaxoSmithKline Outstanding Clinical Scolar
Award
presented for the Highly Rated Abstract: Soverini et al,
“Mutations at contact residues in the ATP-binding site are the main
cause of upfront or acquired resistance to dasatinib in
Philadelphia chromosome-positive (Ph+) leukemia patients”
presentato al 2007 AACR Annual Meeting
- 2010 AACR-Pezcoller Foundation Scholar-in-Training
Award
presented for the abstract: Soverini et al, “First
Application of Whole-Transcriptome Sequencing to a High-Risk
Chronic Myeloid Leukemia (CML) Patient at Diagnosis and at the Time
of Disease Progression to Blast Crisis (BC)” presentato al 2010
AACR Annual Meeting
- 2010 ASCO Cancer Foundation Merit Award
presented for the abstract: Soverini et al, “Metabolizing
Enzymes Genotype and Response in Newly Diagnosed Chronic Myeloid
Leukemia (CML) Patients” presentato al 2010 ASCO Annual Meeting
- 2012 ASCO Cancer Foundation Merit Award
presented for the abstract: Soverini et al, “Bcr-Abl kinase
domain mutations and resistance in Philadelphia-chromosome positive
acute lymphoblastic leukemia from the imatinib to the
second-generation TKI era” presentato al 2012 ASCO Annual
Meeting
PUBLICATIONS
- Tura
“Corso di malattie del sangue e degli organi emolinfopoietici”
quarta (2007), quinta (2011), sesta (2015) e settima (2020) Edizione. Casa Editrice Esculapio, Bologna
- Tura, Cavo, Zinzani
“Hematology: pathophysiology, diagnosis and treatment”
prima edizione in inglese (2018). Casa Editrice Esculapio, Bologna
- “Chronic Myeloid Leukemia Diagnosis and Treatment".
Editor, Rüdiger Hehlmann. 1st ed. Springer International Publishing Switzerland: Springer International. 2016
- “Oxford Specialist Handbooks in Oncology: Myeloproliferative Neoplasms” Editors, Tariq I Mughal and Tiziano Barbui. Oxford University Press. 2020
- “Next generation sequencing nelle leucemie Ph+”. Mattioli 1885. Fidenza. 2018
- Scientific publications in international peer-reviewed journals: 169.
Total IF: 2115,048; average IF, 12,51; total citations: 9709; H-index: 47 (from Scopus Database – accessed on 4/11/2021).
-
First or senior author of 139 abstracts presented at national or international meetings (56 of whom accepted as oral communications)
-
Contributing author of another 451 abstracts submitted to national or international meetings.
